New Fixed-Dose Subcutaneous Option for HER2+ Breast Cancer

New Fixed-Dose Subcutaneous Option for HER2+ Breast Cancer

Episodes

Specialty:

All

Year:

All

EP. 1: Historic Perspectives on HER2+ Breast Cancer

ByMark Pegram, MD, Stanford Women's Cancer Center,Chau Dang, MD, Memorial Sloan Kettering Westchester,Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

September 24th 2020

EP. 2: Dual HER2-Targeted Approaches in Breast Cancer

ByMark Pegram, MD, Stanford Women's Cancer Center,Chau Dang, MD, Memorial Sloan Kettering Westchester,Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

September 24th 2020

EP. 3: Administration of Dual HER2-Targeted Therapy in BC

ByMark Pegram, MD, Stanford Women's Cancer Center,Chau Dang, MD, Memorial Sloan Kettering Westchester,Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

September 24th 2020

EP. 4: Efficacy of Fixed-Dose Subcutaneous Therapy for HER2+ BC

ByMark Pegram, MD, Stanford Women's Cancer Center,Chau Dang, MD, Memorial Sloan Kettering Westchester,Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

September 24th 2020

EP. 5: Clinical Outcomes in HER2+ BC: FeDeriCa and PHranceSCa

ByMark Pegram, MD, Stanford Women's Cancer Center,Chau Dang, MD, Memorial Sloan Kettering Westchester,Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

September 24th 2020

EP. 6: The Impact of Subcutaneous Option for HER2+ BC

ByMark Pegram, MD, Stanford Women's Cancer Center,Chau Dang, MD, Memorial Sloan Kettering Westchester,Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

September 24th 2020

EP. 7: Q&A: Practical Considerations in HER2+ Breast Cancer

ByMark Pegram, MD, Stanford Women's Cancer Center,Chau Dang, MD, Memorial Sloan Kettering Westchester,Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

September 24th 2020

Trending on OncLive

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments

Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC

Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL

Brachytherapy and Minimally Invasive Surgical Techniques Signal the Future of Brain Cancer Management